Purple Biotech Ltd. (PPBT)
Market Closed
2 Mar, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
4. 25
-0.17
-3.93%
$
6.05K Market Cap
- P/E Ratio
- Div Yield
53,370 Volume
-0.92 Eps
$ 4.42
Previous Close Day Range
3.98 4.72
Year Range
3.98 30.5
Want to track PPBT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PPBT earnings report is expected in 6 days (9 Mar 2026)
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
Zacks | 1 year ago
Why Is Purple Biotech Stock Trading Higher On Monday?
On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC).
Benzinga | 1 year ago
What Makes Purple Biotech (PPBT) a New Buy Stock
Purple Biotech (PPBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 1 year ago
